Control 23-valent PPV

BIOLOGICAL3 trials

Sponsors

Sinovac Biotech Co., Ltd

Conditions

Pneumococcal Infections

Phase 3

Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

CompletedNCT02451969

Sinovac Biotech Co., LtdPneumococcal Infections

Start: 2015-04-30End: 2017-02-28Updated: 2017-05-03

Phase 4

A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine

CompletedNCT04989465

Sinovac Biotech Co., LtdPneumococcal Infections

Start: 2021-09-10End: 2021-09-13Updated: 2022-08-12

Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

CompletedNCT05477693

Sinovac Biotech Co., LtdPneumococcal Infections

Start: 2022-10-25End: 2023-04-10Updated: 2023-09-18

Related Papers

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

Human Vaccines & Immunotherapeutics2018-09-1414 citations